3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
60
Unknown
21
Recruiting
21
Active not recruiting
15
Terminated
10
Withdrawn
2
Not yet recruiting
2
Suspended
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Breast
5
Gynecologic
3
Gastrointestinal
2
Thoracic
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Nose Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Ear Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Oxaliplatin
86
Bevacizumab
66
Capecitabine
65
Fluorouracil
48
tislelizumab
41
Gemcitabine
40
Drug Therapy
39
Leucovorin
38
sintilimab
35
Irinotecan
34
lenvatinib
27
Cisplatin
27
HMPL-013
25
S 1 (combination)
23
camrelizumab
22
Immune Checkpoint Inhibitors
21
irinotecan sucrosofate
20
apatinib
20
Surgical Procedures, Operative
20
Radiotherapy
20
Injections
20
130-nm albumin-bound paclitaxel
20
toripalimab
19
Paclitaxel
18
Folfox protocol
17
pembrolizumab
15
Immunotherapy
15
Cetuximab
15
Specimen Handling
14
regorafenib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Surveys and Questionnaires
×
Gastrointestinal
×
Clear all
NCT07361575
2026-02-17
POG
Clinique Paris-Bercy
Phase NA
Not yet recruiting
230 enrolled
NCT06803381
2025-02-06
SOMEST'ALIM2
Hospices Civils de Lyon
Not yet recruiting
96 enrolled